JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McPherson, R. W.
Right arrow Articles by Traystman, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McPherson, R. W.
Right arrow Articles by Traystman, R. J.

Anesthesia & Analgesia, Vol 84, 139-147, Copyright © 1997 by International Anesthesia Research Society


GENERAL ARTICLES

Intraventricular dexmedetomidine decreases cerebral blood flow during normoxia and hypoxia in dogs

RW McPherson, RC Koehler, JR Kirsch and RJ Traystman
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

We tested the hypothesis that a centrally administered alpha 2-receptor agonist could alter the cerebrovascular response to hypoxia, without evidence of systemic absorption of the drug. Beagle dogs were anesthetized with 1.4% isoflurane and exposed to hypoxic hypoxia (Pao2 approximately 22 mm Hg) before and after ventricular-cisternal perfusion with mock cerebrospinal fluid (CSF group, n = 5) or dexmedetomidine (100 micrograms/mL; total dose 300 micrograms; DEX group, n = 6). Cerebral perfusion pressure, Paco2 and arterial oxygen content were controlled and regional cerebral blood flow (CBF; microspheres) and global cerebral metabolic rate for oxygen consumption (CMRO2) were measured. In another group (n = 5), drug distribution under the experimental conditions was assessed by 3H-clonidine administered by ventricular-cisternal perfusion. In the mock CSF group, flow to the cerebral hemispheres increased during hypoxia under baseline conditions and after CSF infusion: 66 +/- 8 to 170 +/- 15 mL.min-1.100 g-1 (265% +/- 24% of baseline value), 83 +/- 9 to 154 +/- 14 mL.min-1.100 g-1 (201% +/- 54% of post-CSF infusion value). DEX decreased normoxic flow in the cerebral hemispheres from 76 +/- 6 to 44 +/- 4 ml.min-1.100 g-1 with decreases in other regions of similar magnitude. After DEX, the absolute flow in all regions during hypoxia was 52%-55% of that prior to DEX (P < 0.05). However, because DEX also decreased normoxic CBF, the percent increase in flow during hypoxia was similar before and after DEX. CMRO2 was not affected by hypoxia prior to DEX. However, after DEX, hypoxia caused a marked reduction in cerebral oxygen delivery (5.2 +/- 1.0 vs 13.7 +/- 2.3 ml.min-1.100 g-1 for the CSF group) and CMRO2 (2.5 +/- 0.6 vs 3.9 +/- 0.6 ml.min-1.100 g- 1). Regional accumulation of intraventricularly administered 3H- clonidine was greatest in periventricular brain structures (e.g., caudate nucleus, dorsal brainstem), and the concentration in the cerebral cortex was approximately 1% of the concentration in the ipsilateral caudate nucleus. We conclude that centrally administered DEX reduces CBF during normoxia and prevents adequate oxygen delivery during hypoxia. The mechanism of DEX-induced CBF reduction is not metabolically mediated, since CMRO2 is maintained at control values during normoxia despite the significant blood flow reduction. We believe that the reduction in CMRO2 during hypoxia in DEX-treated dogs is the result of a reduction of oxygen delivery rather than the underlying mechanism for the observed reduction in CBF during hypoxia.


This article has been cited by other articles:


Home page
Anesth. Analg.Home page
R. C. Prielipp, M. H. Wall, J. R. Tobin, L. Groban, M. A. Cannon, F. H. Fahey, H. D. Gage, D. A. Stump, R. L. James, J. Bennett, et al.
Dexmedetomidine-Induced Sedation in Volunteers Decreases Regional and Global Cerebral Blood Flow
Anesth. Analg., October 1, 2002; 95(4): 1052 - 1059.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
R. C. Prielipp, M. H. Wall, L. Groban, J. R. Tobin, F. H. Fahey, B. A. Harkness, D. A. Stump, R. L. James, M. A. Cannon, J. Bennett, et al.
Reduced Regional and Global Cerebral Blood Flow During Fenoldopam-Induced Hypotension in Volunteers
Anesth. Analg., July 1, 2001; 93(1): 45 - 52.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
Y. Chen, Z. Zhao, W. E. Code, and L. Hertz
A Correlation Between Dexmedetomidine-Induced Biphasic Increases in Free Cytosolic Calcium Concentration and Energy Metabolism in Astrocytes
Anesth. Analg., August 1, 2000; 91(2): 353 - 357.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
H. Ohata, H. Iida, S. Dohi, and Y. Watanabe
Intravenous Dexmedetomidine Inhibits Cerebrovascular Dilation Induced by Isoflurane and Sevoflurane in Dogs
Anesth. Analg., August 1, 1999; 89(2): 370 - 370.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
C. D. Spies and H. Rommelspacher
Alcohol Withdrawal in the Surgical Patient: Prevention and Treatment
Anesth. Analg., April 1, 1999; 88(4): 946 - 946.
[Full Text] [PDF]




Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 1997 by the International Anesthesia Research Society.